Page 66 - Read Online

Gulati et al. Metab Target Organ Damage 2024;4:9 https://dx.doi.org/10.20517/mtod.2023.45 Page 15 of 17

scoping review. J Clin Med 2021;10:5019. DOI PubMed PMC
16. Bambha K, Belt P, Abraham M, et al; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Ethnicity and
nonalcoholic fatty liver disease. Hepatology 2012;55:769-80. DOI PubMed PMC
17. Cullen MR, Lemeshow AR, Russo LJ, Barnes DM, Ababio Y, Habtezion A. Disease-specific health disparities: a targeted review
focusing on race and ethnicity. Healthcare 2022;10:603. DOI PubMed PMC
18. Adejumo AC, Samuel GO, Adegbala OM, et al. Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty
liver disease in the United States. Ann Gastroenterol 2019;32:504-13. DOI PubMed PMC
19. Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of
disease awareness in the United States, 2011-2016. J Intern Med 2020;287:711-22. DOI PubMed
20. Shaheen M, Schrode KM, Tedlos M, Pan D, Najjar SM, Friedman TC. Racial/ethnic and gender disparity in the severity of NAFLD
among people with diabetes or prediabetes. Front Physiol 2023;14:1076730. DOI PubMed PMC
21. Arshad T, Paik JM, Biswas R, Alqahtani SA, Henry L, Younossi ZM. Nonalcoholic fatty liver disease prevalence trends among
adolescents and young adults in the United States, 2007-2016. Hepatol Commun 2021;5:1676-88. DOI PubMed PMC
22. Botero P, Hoy EM, Jimenez MC, Koru-Sengul T, Messiah SE. Predictors of non-alcoholic liver disease in ethnically diverse
overweight children and adolescents. Curr Pediatr Rev 2018;14:130-5. DOI PubMed
23. Fernandes DM, Pantangi V, Azam M, et al. Pediatric nonalcoholic fatty liver disease in New York city: an autopsy study. J Pediatr
2018;200:174-80. DOI
24. Dybbro E, Dongarwar D, Salihu HM, Ihekweazu FD. Trends and disparities in pediatric nonalcoholic fatty liver disease-associated
hospitalizations in the United States. J Pediatr Gastroenterol Nutr 2022;74:503-9. DOI PubMed
25. Browning MG, Khoraki J, DeAntonio JH, et al. Protective effect of black relative to white race against non-alcoholic fatty liver disease
in patients with severe obesity, independent of type 2 diabetes. Int J Obes 2018;42:926-9. DOI
26. Mahabaleshwarkar R, Liu TL, McKillop IH, Spencer M. The association between metabolic syndrome and non-alcoholic fatty liver
disease diagnosis varies by race. Metab Syndr Relat Disord 2022;20:286-94. DOI PubMed
27. Bril F, Portillo-Sanchez P, Liu IC, Kalavalapalli S, Dayton K, Cusi K. Clinical and histologic characterization of nonalcoholic
steatohepatitis in African American patients. Diabetes Care 2018;41:187-92. DOI PubMed
28. Golabi P, Paik J, Hwang JP, Wang S, Lee HM, Younossi ZM. Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD)
among Asian American adults in the United States. Liver Int 2019;39:748-57. DOI PubMed
29. Barritt AS, Watkins S, Gitlin N, et al. Patient determinants for histologic diagnosis of NAFLD in the real world: A TARGET-NASH
study. Hepatol Commun 2021;5:938-46. DOI PubMed PMC
30. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in
obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55:1389-97. DOI
31. Ha J, Chaudhri A, Avirineni A, Pan JJ. Burden of hepatocellular carcinoma among Hispanics in South Texas: a systematic review.
Biomark Res 2017;5:15. DOI PubMed PMC
32. Zarrinpar A, Faltermeier CM, Agopian VG, et al. Metabolic factors affecting hepatocellular carcinoma in steatohepatitis. Liver Int
2019;39:531-9. DOI PubMed PMC
33. Chang ET, Yang J, Alfaro-Velcamp T, So SK, Glaser SL, Gomez SL. Disparities in liver cancer incidence by nativity, acculturation,
and socioeconomic status in California Hispanics and Asians. Cancer Epidemiol Biomarkers Prev 2010;19:3106-18. DOI PubMed
PMC
34. Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. J Investig Med 2014;62:920-6. DOI PubMed PMC
35. Qayed E, Migdal AL, Jagannathan R, Miller LS, Pasquel FJ. Characteristics and outcomes of black and white patients hospitalized
with nonalcoholic steatohepatitis: a nationwide analysis. J Clin Gastroenterol 2023;57:508-14. DOI PubMed
36. Couto CA, Gelape CL, Calmet F, Martin P, Levy C. Effect of ethnicity on liver transplant for hepatocellular carcinoma. Exp Clin
Transplant 2013;11:339-45. DOI PubMed
37. Villalón A, Díaz LA, Fuentes-lópez E, et al. Colorectal adenomas and MAFLD: a cross-sectional study in a Hispanic screening cohort.
Metab Target Organ Damage 2022;2:3. DOI
38. Balakrishnan M, Seth A, Cortes-Santiago N, et al. External validation of four point-of-care noninvasive scores for predicting advanced
hepatic fibrosis in a predominantly Hispanic NAFLD population. Dig Dis Sci 2021;66:2387-93. DOI
39. De Silva S, Li W, Kemos P, et al. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian
descent. Frontline Gastroenterol 2018;9:115-21. DOI PubMed PMC
40. Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids
from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem 2018;293:9232. DOI PubMed PMC
41. Luukkonen PK, Nick A, Hölttä-Vuori M, et al. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty
acids. JCI Insight 2019;4:127902. DOI PubMed PMC
42. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet
2008;40:1461-5. DOI PubMed PMC
43. Auton A, Brooks LD, Durbin RM, et al; 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature
2015;526:68-74. DOI PubMed PMC
44. Roe JD, Garcia LA, Klimentidis YC, Coletta DK. Association of PNPLA3 I148M with liver disease biomarkers in latinos. Hum Hered
2021;86:21-7. DOI PubMed